HC Wainwright Reiterates “Buy” Rating for Entera Bio (NASDAQ:ENTX)

Entera Bio (NASDAQ:ENTX)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $10.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 498.80% from the company’s current price.

Entera Bio Price Performance

Entera Bio stock opened at $1.67 on Monday. The business has a fifty day moving average price of $1.86 and a 200-day moving average price of $1.92. Entera Bio has a 1-year low of $0.52 and a 1-year high of $3.35. The stock has a market capitalization of $59.75 million, a price-to-earnings ratio of -6.42 and a beta of 1.58.

Hedge Funds Weigh In On Entera Bio

An institutional investor recently bought a new position in Entera Bio stock. Signature Estate & Investment Advisors LLC purchased a new stake in shares of Entera Bio Ltd. (NASDAQ:ENTX) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 47,328 shares of the company’s stock, valued at approximately $90,000. Signature Estate & Investment Advisors LLC owned approximately 0.13% of Entera Bio at the end of the most recent quarter. Institutional investors and hedge funds own 14.11% of the company’s stock.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.